Current management of atrial fibrillation: An observational study in NHS primary care

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Kassianos, George ^a   Arden, Chris ^b   Hogan, Simon ^c   Dew, Robert ^d   Fuat, Ahmet ^e  

^a Ringmead Medical Practice   (United Kingdom)

^b Park Surgery   (United Kingdom)

^c Sanofi   (United Kingdom)

^d PH ASSOCIATES   (United Kingdom)

^e Carmel Medical Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; DIGOXIN; SOTALOL;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; FEMALE; HEALTH CARE UTILIZATION; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERTENSION; LENGTH OF STAY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL HEALTH SERVICE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

EID: 84889587811     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003004     Document Type: Article

References (26)

1. Davis RC, Hobbs FD, Kenkre JE, et al. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 2012;14:1553-9.
2. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
3. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
4. Camm A, Kirchhof P, Lip G, et al. Guidelines for management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Guidelines for the management of atrial fibrillation. Eur Heart J 2010;31:2369-429.
5. Wolf PA, Dawber TR, Thomas HE Jr, et al. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke. The Framingham Study. Neurology 1978;28:973-7.
6. National Institute for Health and Clinical Excellence (NICE). Clinical Guideline CG36 - Atrial Fibrillation: The management of atrial fibrillation. 2006. http://www.nice.org.uk/CG36 (accessed 13 Jun 2013).
7. British Medical Association. QOF Guidance 2013/14 QOF Changes. http://bma.org.uk/practical-support-at-work/contracts/independent-contractors/ qof-guidance (accessed 12 Jun 2013).
8. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
9. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-34.
10. Le Heuzey J-Y, Breithardt G, Camm J, et al. The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. Am J Cardiol 2010;105:687-93.
11. Steg PG, Alam S, Chiang C-E, et al. Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 2012;98:195-201.
12. Cohen A, Dallongeville J, Durand-Zaleski I, et al. Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch Cardiovasc Dis 2010;103:376-87.
13. Kakkar AK, Mueller I, Bassand J-P, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE 2013;8:e63479.
14. NHS Connecting for Health: Read Codes. http://www.connectingforhealth. nhs.uk/systemsandservices/data/uktc/readcodes (accessed 13 Jun 2013).
15. Humphries K, Kerr C, Connolly S, et al. New-onset atrial fibrillation sex differences in presentation, treatment, and outcome. Circulation 2001;103:2365-70.
16. DiMarco J, Flaker G, Waldo A. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study. Am Heart J 2005;149:650-6.
17. Lip G, Boos C. Antithrombotic treatment in atrial fibrillation. Heart 2006;92:155-61.
18. Mant J, Hobbs F, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503.
19. Aguilar MI, Hart R, Pearce L. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007;3:CD006186.
20. Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-rheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004;4:CD000187.
21. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67.
22. Holt TA, Hunter TD, Gunnarsson C, et al. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey. Br J Gen Pract 2012;62:e710-17.
23. Camm JA, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33:2719-47.
24. NHS Improvement. Anticoagulation for Atrial Fibrillation - a simple overview to support the commissioning of quality services. 2011. http://www.improvement.nhs.uk/heart/Heartresources/publications.aspx (accessed 12 Jun 2013).
25. National Institute for Health and Care Excellence (NICE). Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249). London, England: NICE, 2012. http://publications.nice.org. uk/dabigatran-etexilate-for-the-prevention-of-stroke-and-systemic-embolism-in- atrial-fibrillation-ta249 (accessed 12 Jun 2013).
26. Gallagher AM, Rietbrock S, Plumb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008;6:1500-6.